Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins
- Registration Number
- NCT00657319
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard® insulins after 6 months of their switch to analog premix insulin NovoMix® 30 therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3495
Inclusion Criteria
- Subjects diagnosed with type 2 diabetes previously treated with BHI for at least 12 months
- Analogue premix administration for the last 6 months
Exclusion Criteria
- Known or suspected allergy to insulin aspart
- Newly diagnosed diabetes
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description A biphasic insulin aspart 30 -
- Primary Outcome Measures
Name Time Method HbA1C 6 months
- Secondary Outcome Measures
Name Time Method General conditions (reason of switch, BMI, selected laboratory parameters, quality of care) 6 months
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇭🇺Budapest, Hungary